{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:27:02Z","timestamp":1792466822339,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,9,29]],"date-time":"2015-09-29T00:00:00Z","timestamp":1443484800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,9,29]],"date-time":"2015-09-29T00:00:00Z","timestamp":1443484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1038\/leu.2015.261","type":"journal-article","created":{"date-parts":[[2015,9,29]],"date-time":"2015-09-29T06:40:47Z","timestamp":1443508847000},"page":"48-56","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":274,"title":["Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia"],"prefix":"10.1038","volume":"30","author":[{"given":"M","family":"Pfirrmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Baccarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Saussele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Guilhot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Cervantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Ossenkoppele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V S","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Castagnetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Hasford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Hehlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Simonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,29]]},"reference":[{"key":"BFleu2015261_CR1","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1182\/blood.V114.22.462.462","volume":"114","author":"M Deininger","year":"2009","unstructured":"Deininger M, O'Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009; 114: 462 (abstr 1126).","journal-title":"Blood"},{"key":"BFleu2015261_CR2","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","volume":"32","author":"R Hehlmann","year":"2014","unstructured":"Hehlmann R, Muller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol 2014; 32: 415\u2013423.","journal-title":"J Clin Oncol"},{"key":"BFleu2015261_CR3","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1182\/blood.V122.21.258.258","volume":"122","author":"F Castagnetti","year":"2013","unstructured":"Castagnetti F, Gugliotta G, Breccia M, Specchia G, Intermesoli T, Capucci A et al. Frontline treatment with imatinib mesylate in chronic myeloid leukemia patients in early chronic phase: a very long-term analysis by the GIMEMA CML Working Party. Blood 2013; 122: 258 (abstr 258).","journal-title":"Blood"},{"key":"BFleu2015261_CR4","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","volume":"118","author":"J Hasford","year":"2011","unstructured":"Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 2011; 118: 686\u2013692.","journal-title":"Blood"},{"key":"BFleu2015261_CR5","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1038\/leu.2013.171","volume":"27","author":"VS Hoffmann","year":"2013","unstructured":"Hoffmann VS, Baccarani M, Lindoerfer D, Castagnetti F, Turkina A, Zaritsky A et al. The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib. Leukemia 2013; 27: 2016\u20132022.","journal-title":"Leukemia"},{"key":"BFleu2015261_CR6","first-page":"423","volume-title":"Cancer Clinical Trials\u2014Methods and Practice","author":"DP Byar","year":"1984","unstructured":"Byar DP . Identification of prognostic factors. In: Buyse ME, Staquet MJ, Sylvester RJ (eds). Cancer Clinical Trials\u2014Methods and Practice. Oxford University Press: Oxford, 1984; pp 423\u2013441."},{"key":"BFleu2015261_CR7","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","volume":"90","author":"J Hasford","year":"1998","unstructured":"Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998; 90: 850\u2013858.","journal-title":"J Natl Cancer Inst"},{"key":"BFleu2015261_CR8","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O'Brien","year":"2003","unstructured":"O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994\u20131004.","journal-title":"N Engl J Med"},{"key":"BFleu2015261_CR9","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251\u20132259.","journal-title":"N Engl J Med"},{"key":"BFleu2015261_CR10","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260\u20132270.","journal-title":"N Engl J Med"},{"key":"BFleu2015261_CR11","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","volume":"363","author":"C Preudhomme","year":"2010","unstructured":"Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 2010; 363: 2511\u20132521.","journal-title":"N Engl J Med"},{"key":"BFleu2015261_CR12","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","volume":"29","author":"R Hehlmann","year":"2011","unstructured":"Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Muller MC, Pletsch N et al. Tolerability-adapted imatinib 800\u2009mg\/d versus 400\u2009mg\/d versus 400\u2009mg\/d plus interferon-{alpha} in newly diagnosed chronic myeloid leukemia. J Clin Oncol 2011; 29: 1634\u20131642.","journal-title":"J Clin Oncol"},{"key":"BFleu2015261_CR13","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","volume":"30","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kim D-W, Kantarjian HM, Br\u00fcmmendorf TH, Dyagil I, Griskevicius L et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 2012; 30: 3486\u20133492.","journal-title":"J Clin Oncol"},{"key":"BFleu2015261_CR14","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1182\/blood-2012-02-410688","volume":"120","author":"JP Radich","year":"2012","unstructured":"Radich JP, Kopecky KJ, Appelbaum FR, Kamel-Reid S, Stock W, Malnassy G et al. A randomized trial of dasatinib 100\u2009mg versus imatinib 400\u2009mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood 2012; 120: 3898\u20133905.","journal-title":"Blood"},{"key":"BFleu2015261_CR15","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"JE Sokal","year":"1984","unstructured":"Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE et al. Prognostic discrimination in \u2018good-risk\u2019 chronic granulocytic leukemia. Blood 1984; 63: 789\u2013799.","journal-title":"Blood"},{"key":"BFleu2015261_CR16","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia. 2013 Blood 2013; 122: 872\u2013884.","journal-title":"Blood"},{"key":"BFleu2015261_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3294-8","volume-title":"Modeling Survival Data: Extending the Cox Model","author":"TM Therneau","year":"2000","unstructured":"Therneau TM, Grambsch PM . Modeling Survival Data: Extending the Cox Model. Springer: New York, 2000."},{"key":"BFleu2015261_CR18","volume-title":"The Statistical Analysis of Failure Time Data","author":"JD Kalbfleisch","year":"1980","unstructured":"Kalbfleisch JD, Prentice RL . The Statistical Analysis of Failure Time Data. Wiley: New York, 1980."},{"key":"BFleu2015261_CR19","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1002\/sim.1070","volume":"21","author":"JB Choudhury","year":"2002","unstructured":"Choudhury JB . Non-parametric confidence interval estimation for competing risks analysis: application to contraceptive data. Stat Med 2002; 21: 1129\u20131144.","journal-title":"Stat Med"},{"key":"BFleu2015261_CR20","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1214\/aos\/1176350951","volume":"16","author":"RJ Gray","year":"1988","unstructured":"Gray RJ . A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141\u20131154.","journal-title":"Ann Stat"},{"key":"BFleu2015261_CR21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1541-0420.2011.01640.x","volume":"68","author":"M Pohar-Perme","year":"2012","unstructured":"Pohar-Perme M, Stare J, Est\u00e8ve J . On estimation in relative survival. Biometrics 2012; 68: 113\u2013120.","journal-title":"Biometrics"},{"key":"BFleu2015261_CR22","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.cmpb.2006.01.004","volume":"81","author":"M Pohar","year":"2006","unstructured":"Pohar M, Stare J . Relative survival analysis in R. Comput Meth Prog Bio 2006; 81: 272\u2013278.","journal-title":"Comput Meth Prog Bio"},{"key":"BFleu2015261_CR23","unstructured":"Human Mortality Database: University of California, Berkeley (USA), and Max Planck Institute of Demographic Research (Germany): the human mortality database provides mortality and population data on various countries. 05\/2014 update. Available at http:\/\/www.mortality.org\/ or http:\/\/www.humanmortality.de\/."},{"key":"BFleu2015261_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/9780470770771","volume-title":"Multivariable Model-Building: A Pragmatic Approach to Regression Analysis Based on Fractional Polynomials for Continuous Variables","author":"P Royston","year":"2008","unstructured":"Royston P, Sauerbrei W . Multivariable Model-Building: A Pragmatic Approach to Regression Analysis Based on Fractional Polynomials for Continuous Variables. John Wiley & Sons: Chichester, 2008."},{"key":"BFleu2015261_CR25","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ . A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496\u2013509.","journal-title":"J Am Stat Assoc"},{"key":"BFleu2015261_CR26","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1002\/sim.5762","volume":"32","author":"D Kuk","year":"2013","unstructured":"Kuk D, Varadhan R . Model selection in competing risks regression. Stat Med 2013; 32: 3077\u20133088.","journal-title":"Stat Med"},{"key":"BFleu2015261_CR27","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511802843","volume-title":"Bootstrap Methods and Their application","author":"AC Davison","year":"1997","unstructured":"Davison AC, Hinkley DV . Bootstrap Methods and Their application. Cambridge University Press: Cambridge, 1997."},{"key":"BFleu2015261_CR28","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1093\/jnci\/86.11.829","volume":"86","author":"DG Altman","year":"1994","unstructured":"Altman DG, Lausen B, Sauerbrei W, Schumacher M . Dangers of using \u2018optimal\u2019 cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994; 86: 829\u2013835.","journal-title":"J Natl Cancer Inst"},{"key":"BFleu2015261_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4899-3324-9","volume-title":"Density Estimation for Statistics and Data Analysis","author":"BW Silverman","year":"1986","unstructured":"Silverman BW . Density Estimation for Statistics and Data Analysis. Chapman and Hall:: London, 1986."},{"key":"BFleu2015261_CR30","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.1016\/j.csda.2005.07.015","volume":"50","author":"W Sauerbrei","year":"2006","unstructured":"Sauerbrei W, Meier-Hirmer C, Benner A, Royston P . Multivariable regression model building by using fractional polynomials: description of SAS, STATA and R programs. Comput Stat Data An 2006; 50: 3464\u20133485.","journal-title":"Comput Stat Data An"},{"key":"BFleu2015261_CR31","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1038\/bmt.2009.359","volume":"45","author":"L Scrucca","year":"2010","unstructured":"Scrucca L, Santucci A, Aversa F . Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transpl 2010; 45: 1388\u20131395.","journal-title":"Bone Marrow Transpl"},{"key":"BFleu2015261_CR32","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1182\/blood-2007-08-107482","volume":"111","author":"W Deenik","year":"2008","unstructured":"Deenik W, van der Holt B, Verhoef GE, Smit WM, Kersten MJ, Kluin-Nelemans HC et al. Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia. Blood 2008; 111: 2581\u20132588.","journal-title":"Blood"},{"key":"BFleu2015261_CR33","doi-asserted-by":"publisher","first-page":"5591","DOI":"10.1182\/blood-2010-12-324228","volume":"117","author":"G Gugliotta","year":"2011","unstructured":"Gugliotta G, Castagnetti F, Palandri F, Breccia M, Intermesoli T, Capucci A et al. Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. Blood 2011; 117: 5591\u20135599.","journal-title":"Blood"},{"key":"BFleu2015261_CR34","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1182\/blood-2011-02-336685","volume":"118","author":"B Simonsson","year":"2011","unstructured":"Simonsson B, Gedde-Dahl T, Markev\u00e4rn B, Remes K, Stentoft J, Almqvist A et al. Combination of pegylated IFN-\u03b12b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood 2011; 118: 3228\u20133235.","journal-title":"Blood"},{"key":"BFleu2015261_CR35","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.3324\/haematol.2009.021154","volume":"95","author":"F Cervantes","year":"2010","unstructured":"Cervantes F, L\u00f3pez-Garrido P, Montero M-I, Jonte F, Mart\u00ednez J, Hern\u00e1ndez-Boluda J-C et al. Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group. Haematologica 2010; 95: 1317\u20131324.","journal-title":"Haematologica"},{"key":"BFleu2015261_CR36","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/leu.2015.73","volume":"29","author":"VS Hoffmann","year":"2015","unstructured":"Hoffmann VS, Baccarani M, Hasford J, Lindoerfer D, Burgstaller S, Sertic D et al. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. Leukemia 2015; 29: 1336\u20131343.","journal-title":"Leukemia"},{"key":"BFleu2015261_CR37","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00277-013-1937-4","volume":"93","author":"L Kalmanti","year":"2014","unstructured":"Kalmanti L, Saussele S, Lauseker M, Proetel U, Muller MC, Hanfstein B et al. Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. Ann Hematol 2014; 93: 71\u201380.","journal-title":"Ann Hematol"},{"key":"BFleu2015261_CR38","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/annonc\/mdu490","volume":"26","author":"F Castagnetti","year":"2015","unstructured":"Castagnetti F, Gugliotta G, Baccarani M, Breccia M, Specchia G, Levato L et al. Differences among young adults, adults and elderly chronic myeloid leukemia patients. Ann Oncol 2015; 26: 185\u2013192.","journal-title":"Ann Oncol"},{"key":"BFleu2015261_CR39","first-page":"205","volume-title":"Chronic Myeloid Leukemia \u2013 Biology and Treatment","author":"J Hasford","year":"2001","unstructured":"Hasford J, Pfirrmann M, Hehlmann R, Shepherd P, Guilhot F, Mahon FX et al. Prognostic factors. In: Carella AM, Daley G, Eaves C, Goldman J, Hehlmann R (eds). Chronic Myeloid Leukemia \u2013 Biology and Treatment. Martin Dunitz: London, 2001; pp 205\u2013223."},{"key":"BFleu2015261_CR40","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/sj.bmt.1705727","volume":"40","author":"L Scrucca","year":"2007","unstructured":"Scrucca L, Santucci A, Aversa F . Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transpl 2007; 40: 381\u2013387.","journal-title":"Bone Marrow Transpl"},{"key":"BFleu2015261_CR41","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1038\/leu.2011.116","volume":"25","author":"M Pfirrmann","year":"2011","unstructured":"Pfirrmann M, Hochhaus A, Lauseker M, Saussele S, Hehlmann R, Hasford J . Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia. Leukemia 2011; 25: 1433\u20131438.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2015261.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2015261","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2015261.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:03:55Z","timestamp":1648742635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2015261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,29]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["BFleu2015261"],"URL":"https:\/\/doi.org\/10.1038\/leu.2015.261","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,29]]},"assertion":[{"value":"2 September 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MP acted as a consultant for and received honoraria from Novartis and Bristol-Myers Squibb. MB served on the speakers\u2019 bureau of and received honoraria from ARIAD, Bristol-Myers Squibb, Novartis and Pfizer and acted as a consultant for ARIAD and Novartis. SS acted as a consultant for Novartis, and Pfizer, received honoraria ARIAD, Bristol-Myers Squibb, Novartis and Pfizer, and received research funding from Bristol-Myers Squibb and Novartis. FC served on the speakers\u2019 bureau of and received honoraria from ARIAD, Bristol-Myers Squibb and Novartis and acted as a consultant for ARIAD and Pfizer. GO acted as a consultant for ARIAD, Bristol-Myers Squibb, Celgene, Johnson & Johnson, Novartis and Roche and received research funding from Celgene and Novartis. VSH received research funding from Novartis. F Castagnetti acted as a consultant for and received honoraria from ARIAD, Bristol-Myers Squibb, Novartis and Pfizer. JH received honoraria from Bristol-Myers Squibb and research funding from Novartis; RH received research funding from Bristol-Myers Squibb and Novartis. BS acted as a consultant for and received honoraria from Novartis and Bristol-Myers Squibb.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}